PE20160238A1 - Composicion antituberculosa que comprende rifampicina, isoniazid, etambutol y pirazinamida y su proceso de preparacion - Google Patents
Composicion antituberculosa que comprende rifampicina, isoniazid, etambutol y pirazinamida y su proceso de preparacionInfo
- Publication number
- PE20160238A1 PE20160238A1 PE2016000091A PE2016000091A PE20160238A1 PE 20160238 A1 PE20160238 A1 PE 20160238A1 PE 2016000091 A PE2016000091 A PE 2016000091A PE 2016000091 A PE2016000091 A PE 2016000091A PE 20160238 A1 PE20160238 A1 PE 20160238A1
- Authority
- PE
- Peru
- Prior art keywords
- pyrazinamide
- ethambutol
- isoniazid
- preparation process
- antituberculosis
- Prior art date
Links
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 title abstract 6
- 229960000285 ethambutol Drugs 0.000 title abstract 3
- 229960003350 isoniazid Drugs 0.000 title abstract 3
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 title abstract 3
- 229960005206 pyrazinamide Drugs 0.000 title abstract 3
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 title abstract 2
- 229960001225 rifampicin Drugs 0.000 title abstract 2
- 230000002365 anti-tubercular Effects 0.000 title 1
- 239000008187 granular material Substances 0.000 abstract 3
- 239000011230 binding agent Substances 0.000 abstract 2
- 238000005469 granulation Methods 0.000 abstract 2
- 230000003179 granulation Effects 0.000 abstract 2
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000002356 single layer Substances 0.000 abstract 1
- 201000008827 tuberculosis Diseases 0.000 abstract 1
- 238000005550 wet granulation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invencion se refiere a un comprimido monocapa para uso en el tratamiento de la tuberculosis que comprenden una mezcla de: a) granulos que comprenden isoniazid, pirazinamida, etambutol o una sal farmaceuticamente aceptable de este y al menos un aglutinante de granulacion, rifampicina en forma de polvo, excipientes extragranulares, en el que todos los granulos tienen un tamano de particula que es menor de 0,599 mm, preferiblemente menor de 0,5 mm, mas preferiblemente menor de 0,422 mm. Tambien se refiere a su proceso de preparacion caracterizado porque comprende una etapa de granulacion humeda de isoniazid, pirazinamida y etambutol con una disolucion acuosa de un aglutinante de granulacion para obtener granulos
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN3343CH2013 | 2013-07-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20160238A1 true PE20160238A1 (es) | 2016-05-05 |
Family
ID=51212860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2016000091A PE20160238A1 (es) | 2013-07-26 | 2014-07-22 | Composicion antituberculosa que comprende rifampicina, isoniazid, etambutol y pirazinamida y su proceso de preparacion |
Country Status (18)
Country | Link |
---|---|
US (1) | US9814711B2 (es) |
EP (1) | EP3024445B1 (es) |
JP (1) | JP2017501117A (es) |
CN (1) | CN105407874A (es) |
AU (1) | AU2014295100B2 (es) |
CA (1) | CA2918828A1 (es) |
CL (1) | CL2016000180A1 (es) |
HK (1) | HK1218721A1 (es) |
IL (1) | IL243370A0 (es) |
MX (1) | MX2016001156A (es) |
MY (1) | MY174007A (es) |
PE (1) | PE20160238A1 (es) |
PH (1) | PH12016500118A1 (es) |
RU (1) | RU2672879C2 (es) |
SG (1) | SG11201510699WA (es) |
TW (1) | TW201601716A (es) |
WO (1) | WO2015011163A1 (es) |
ZA (1) | ZA201600108B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2016001155A (es) | 2013-07-26 | 2016-04-29 | Sanofi Sa | Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido dispersable que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion. |
KR20180126511A (ko) * | 2016-04-08 | 2018-11-27 | 큐어테크 바이오 에이비 | 고리-융합된 티아졸리노 2-피리돈, 이의 제조 방법 및 결핵의 치료 및/또는 예방에 있어서의 그 용도 |
EP3691619A1 (en) * | 2017-10-05 | 2020-08-12 | Quretech Bio AB | Ring-fused thiazolino 2-pyridones in combination with a drug against tuberculosis |
WO2019162964A1 (en) * | 2018-02-23 | 2019-08-29 | Indian Institute Of Science | Anti-tubercular composition, and combinatorial implementations thereof |
CN108186638A (zh) * | 2018-03-08 | 2018-06-22 | 重庆华邦制药有限公司 | 异烟肼的药物组合物 |
AU2022405079A1 (en) * | 2021-12-07 | 2024-06-27 | An2 Therapeutics, Inc. | Combinations |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1217912A (zh) | 1997-11-26 | 1999-06-02 | 岑冠新 | 复方利福喷丁制剂及制备方法 |
NZ518216A (en) * | 2000-08-09 | 2004-11-26 | Panacea Biotec Ltd | Pharmaceutical compositions of anti-tubercular drugs and process for their preparation |
WO2002087547A1 (en) | 2001-04-27 | 2002-11-07 | Lupin Limited | An improved process for preparation of four-drug anti-tubercular fixed dose combination |
RU2195937C1 (ru) * | 2002-02-06 | 2003-01-10 | НИИ молекулярной медицины ММА им. И.М.Сеченова | Комбинированный противотуберкулезный препарат (ризобутол) |
US20050059719A1 (en) | 2003-09-16 | 2005-03-17 | Badawy Sherif Ibrahim Farag | Solid dosage formulation containing a Factor Xa inhibitor and method |
EP1711182A1 (en) * | 2004-02-04 | 2006-10-18 | Vinay Ramakant Sapte | Oral cyclodextrin complexes of antituberculosis drugs |
TWI368509B (en) | 2005-10-05 | 2012-07-21 | Otsuka Pharma Co Ltd | Antituberculous therapeutic drugs and kit containing the same |
CN1989966B (zh) | 2005-12-30 | 2011-06-08 | 重庆华邦制药股份有限公司 | 含利福平和异烟肼的药物组合物 |
CN1857280A (zh) | 2006-04-11 | 2006-11-08 | 济南帅华医药科技有限公司 | 一种复方抗结核药物缓释制剂 |
KR101197277B1 (ko) | 2009-02-05 | 2012-11-05 | (주) 벡스코아 | 경구용 결핵의 치료용 또는 예방용 고형 제형 |
AP2012006119A0 (en) | 2009-07-31 | 2012-02-29 | Cadila Pharmaceuticals Ltd | Pharmaceutical composition of isoniazid. |
WO2012013756A2 (fr) * | 2010-07-28 | 2012-02-02 | Laboratoires Pharma 5 | Procédé de préparation de comprimés contenant en association la rifampicine, l'isoniazide, la pyrazinamide, et éventuellement l'ethambutol |
US8470365B2 (en) * | 2010-07-29 | 2013-06-25 | Taiwan Biotech Co., Ltd. | Process for preparation of anti-tubercular combination and pharmaceutical composition prepared therefrom |
MX2016001155A (es) | 2013-07-26 | 2016-04-29 | Sanofi Sa | Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido dispersable que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion. |
RU2682178C2 (ru) | 2013-07-26 | 2019-03-15 | Санофи | Противотуберкулезная стабильная фармацевтическая композиция в форме таблетки с покрытием, содержащей гранулированный изониазид и гранулированный рифапентин, и способ ее приготовления |
-
2014
- 2014-07-22 RU RU2016106336A patent/RU2672879C2/ru not_active IP Right Cessation
- 2014-07-22 PE PE2016000091A patent/PE20160238A1/es unknown
- 2014-07-22 CN CN201480041951.1A patent/CN105407874A/zh active Pending
- 2014-07-22 CA CA2918828A patent/CA2918828A1/en not_active Abandoned
- 2014-07-22 MY MYPI2015704808A patent/MY174007A/en unknown
- 2014-07-22 WO PCT/EP2014/065763 patent/WO2015011163A1/en active Application Filing
- 2014-07-22 JP JP2016528511A patent/JP2017501117A/ja not_active Ceased
- 2014-07-22 EP EP14741897.4A patent/EP3024445B1/en not_active Not-in-force
- 2014-07-22 SG SG11201510699WA patent/SG11201510699WA/en unknown
- 2014-07-22 AU AU2014295100A patent/AU2014295100B2/en not_active Expired - Fee Related
- 2014-07-22 MX MX2016001156A patent/MX2016001156A/es unknown
- 2014-07-22 US US14/906,870 patent/US9814711B2/en not_active Expired - Fee Related
- 2014-07-25 TW TW103125583A patent/TW201601716A/zh unknown
-
2015
- 2015-12-28 IL IL243370A patent/IL243370A0/en unknown
-
2016
- 2016-01-06 ZA ZA2016/00108A patent/ZA201600108B/en unknown
- 2016-01-19 PH PH12016500118A patent/PH12016500118A1/en unknown
- 2016-01-22 CL CL2016000180A patent/CL2016000180A1/es unknown
- 2016-06-14 HK HK16106815.2A patent/HK1218721A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP3024445B1 (en) | 2019-01-09 |
MX2016001156A (es) | 2016-04-29 |
CA2918828A1 (en) | 2015-01-29 |
WO2015011163A1 (en) | 2015-01-29 |
PH12016500118A1 (en) | 2016-04-25 |
IL243370A0 (en) | 2016-02-29 |
RU2672879C2 (ru) | 2018-11-20 |
AU2014295100B2 (en) | 2019-01-03 |
HK1218721A1 (zh) | 2017-03-10 |
US9814711B2 (en) | 2017-11-14 |
JP2017501117A (ja) | 2017-01-12 |
CN105407874A (zh) | 2016-03-16 |
MY174007A (en) | 2020-03-03 |
AU2014295100A1 (en) | 2016-02-11 |
RU2016106336A3 (es) | 2018-05-17 |
EP3024445A1 (en) | 2016-06-01 |
SG11201510699WA (en) | 2016-01-28 |
RU2016106336A (ru) | 2017-08-31 |
CL2016000180A1 (es) | 2016-06-24 |
US20160158226A1 (en) | 2016-06-09 |
ZA201600108B (en) | 2017-04-26 |
TW201601716A (zh) | 2016-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20160238A1 (es) | Composicion antituberculosa que comprende rifampicina, isoniazid, etambutol y pirazinamida y su proceso de preparacion | |
CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
CL2018003291A1 (es) | Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018). | |
UY35573A (es) | Derivados de sulfamoilpirrolamida y su uso como m edicamentos para el tratamiento de la hepatitis b | |
UY36766A (es) | Derivados de sulfamoilarilamida ciclados como inhibidores del vhb, procesos de preparación y composiciones farmacéuticas que los contienen | |
SA515361055B1 (ar) | نواتج تكتل قابلة للاستنشاق من جسيمات حاملة مسامية وعقار بحجم الميكرون | |
CL2016001874A1 (es) | Forma de dosificación oral sólida de liberación modificada que comprende pridopidina y un excipiente de control de velocidad; formulación farmacéutica que comprende a la forma de dosificación; uso de la forma de dosificación o de la formulación farmacéutica para tratar una enfermedad neurodegenerativa o relacionada con dopamina, como la enfermedad de huntington, entre otras. | |
JP2015078230A5 (es) | ||
CL2015002164A1 (es) | Formulación combinada de dos compuesos antivirales. | |
CL2015003072A1 (es) | Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas. | |
CR20160130A (es) | Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso | |
MX2015013845A (es) | Polvos secos de tiotropio. | |
PE20160550A1 (es) | Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona | |
ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
AR128459A2 (es) | Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación | |
DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
AR107935A1 (es) | Uso del compuesto 6-(4-(2,3-dimetilfenoxi)piperidin-1-il)metil)pirimidino-2,4(1h,3h)-diona o una sal farmacéuticamente aceptable del mismo para preparar un medicamento, combinación y composición farmacéutica que comprende dicho compuesto | |
CL2016000183A1 (es) | Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido redispersable que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación | |
PH12016502272A1 (en) | Ceritinib formulation | |
CL2016000182A1 (es) | Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación | |
IN2014CH02034A (es) | ||
AR109253A1 (es) | Composición de teneligliptina y metformina y proceso para prepararla | |
MX2019001190A (es) | Composicion de liberacion sostenida que comprende tolcapona micronizada. | |
CL2016000384A1 (es) | Uso de una forma de dosificación de liberación extendida de arbaclofeno que comprende una primera dosis y una segunda dosis para administrar en un período de 24 horas, donde la primera dosis es administrada en estado alimentado y la segunda dosis en estado de ayuno; o la primera dosis en estado de ayuno y la segunda dosis en estado alimentado | |
AR106847A1 (es) | Formulaciones farmacéuticas tópicas para tratar afecciones inflamatorias |